Cell-based treatment for monocrotaline-induced rat pulmonary arterial hypertension

Cytotherapy

Volumn 15, Issue 2, 2013, Pages 209-223

  Yen, Chia Hung ^a   Tsai, Tzu Hsien ^b   Leu, Steve ^c   Chen, Yung Lung ^b   Chang, Li Teh ^d   Chai, Han Tan ^b   Chung, Sheng Ying ^b   Chua, Sarah ^b   Tsai, Ching Yen ^e   Chang, Hsueh Wen ^f   Ko, Sheung Fat ^c   Sun, Cheuk Kwan ^g   Yip, Hon Kan ^b,c,h  

^a NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b Division of Cardiology   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d MEIHO UNIVERSITY   (Taiwan)

^e INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^f NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^g I SHOU UNIVERSITY   (Taiwan)

^h CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Bone marrow derived endothelial progenitor cells; Combined therapy; MCT induced pulmonary hypertension; Sildenafil

Indexed keywords

BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; CASPASE 3; CONNEXIN 43; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GELATINASE B; INTERLEUKIN 10; MESSENGER RNA; MONOCROTALINE; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; SILDENAFIL; SMAD1 PROTEIN; SMAD3 PROTEIN; SMAD5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SULFONE; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERIOLE; ARTICLE; BONE MARROW CELL; CARDIOPULMONARY HEMODYNAMICS; CONTROLLED STUDY; ENDOTHELIAL PROGENITOR CELL; HEART RIGHT VENTRICLE; LONG TERM CARE; LUNG; MALE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; ANIMAL; BIOLOGICAL THERAPY; CHEMICALLY INDUCED DISORDER; CYTOLOGY; ENDOTHELIUM CELL; HUMAN; MULTIMODALITY CANCER THERAPY; SPRAGUE DAWLEY RAT; STEM CELL; STEM CELL TRANSPLANTATION; TIME; TRANSPLANTATION;

ANIMALS; COMBINED MODALITY THERAPY; ENDOTHELIAL CELLS; HUMANS; HYPERTENSION, PULMONARY; MALE; MONOCROTALINE; PIPERAZINES; PURINES; RATS; RATS, SPRAGUE-DAWLEY; STEM CELL TRANSPLANTATION; STEM CELLS; SULFONES; TIME; TISSUE THERAPY; VASODILATOR AGENTS;

EID: 84875461441     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2012.09.002     Document Type: Article

References (33)

1. Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, et al. Histopathology of primary pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation. 1989;80:1198-206.
2. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet. 2003;361:1533-44.
3. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-36.
4. Zhao YY, Malik AB. A novel insight into the mechanism of pulmonary hypertension involving caveolin-1 deficiency and endothelial nitric oxide synthase activation. Trends Cardiovasc Med. 2009;19:238-42.
5. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343-9.
6. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol. 1996;35:989-93.
7. Rhodes CJ, Davidson A, Gibbs JS, Wharton J, Wilkins MR. Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther. 2009;121:69-88.
8. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004;169:39-45.
9. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group.NEngl J Med. 1996;334:296-302.
10. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119-23.
11. Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L, Fadel E, Dartevelle P, et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation. 2006;113:1857-64.
12. Sanchez O, Marcos E, Perros F, Fadel E, Tu L, Humbert M, et al. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2007;176:1041-7.
13. Tuder RM, Marecki JC, Richter A, Fijalkowska I, Flores S. Pathology of pulmonary hypertension. Clin Chest Med. 2007; 28:23-42. vii.
14. Meyrick BO, Reid LM. Crotalaria-induced pulmonary hypertension: uptake of 3H-thymidine by the cells of the pulmonary circulation and alveolar walls. Am J Pathol. 1982; 106:84-94.
15. Marsboom G, Janssens S. Endothelial progenitor cells: new perspectives and applications in cardiovascular therapies. Expert Rev Cardiovasc Ther. 2008;6:687-701.
16. Luttun A, Carmeliet G, Carmeliet P. Vascular progenitors: from biology to treatment. Trends Cardiovasc Med. 2002;12: 88-96.
17. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol. 2004; 287:C572-9.
18. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res. 2005;96:442-50.
19. Takahashi M, Nakamura T, Toba T, Kajiwara N, Kato H, Shimizu Y. Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs. Tissue Eng. 2004;10:771-9.
20. Wang XX, Zhang FR, Shang YP, Zhu JH, Xie XD, Tao QM, et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol. 2007;49:1566-71.
21. Yip HK, Chang LT, Sun CK, Sheu JJ, Chiang CH, Youssef AA, et al. Autologous transplantation of bone marrow-derived endothelial progenitor cells attenuates monocrotaline-induced pulmonary arterial hypertension in rats. Crit Care Med. 2008;36:873-80.
22. Raoul W, Wagner-Ballon O, Saber G, Hulin A, Marcos E, Giraudier S, et al. Effects of bone marrow-derived cells on monocrotaline- and hypoxia-induced pulmonary hypertension in mice. Respir Res. 2007;8:8.
23. Yen CH, Leu S, Lin YC, Kao YH, Chang LT, Chua S, et al. Sildenafil limits monocrotaline-induced pulmonary hypertension in rats through suppression of pulmonary vascular remodeling. J Cardiovasc Pharmacol. 2010;55:574-84.
24. Sun CK, Lee FY, Sheu JJ, Yuen CM, Chua S, Chung SY, et al. Early combined treatment with cilostazol and bone marrow-derived endothelial progenitor cells markedly attenuates pulmonary arterial hypertension in rats. J Pharmacol Exp Ther. 2009;330:718-26.
25. Kee HJ, Sohn IS, Nam KI, Park JE, Qian YR, Yin Z, et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation. 2006;113:51-9.
26. Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, Karoubi G, Courtman DW, Zucco L, et al. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-offunction mutations in the pathogenesis of pulmonary hypertension. Circ Res. 2006;98:209-17.
27. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S20-31.
28. Lerner DL, Yamada KA, Schuessler RB, Saffitz JE. Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circulation. 2000;101:547-52.
29. Kirchhoff S, Nelles E, Hagendorff A, Kruger O, Traub O, Willecke K. Reduced cardiac conduction velocity and predisposition to arrhythmias in connexin40-deficient mice. Curr Biol. 1998;8:299-302.
30. Uzzaman M, Honjo H, Takagishi Y, Emdad L, Magee AI, Severs NJ, et al. Remodeling of gap junctional coupling in hypertrophied right ventricles of rats with monocrotaline- induced pulmonary hypertension. Circ Res. 2000;86: 871-8.
31. Blackburn JP, Peters NS, Yeh HI, Rothery S, Green CR, Severs NJ. Upregulation of connexin43 gap junctions during early stages of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15:1219-28.
32. Yeh HI, Lupu F, Dupont E, Severs NJ. Upregulation of connexin43 gap junctions between smooth muscle cells after balloon catheter injury in the rat carotid artery. Arterioscler Thromb Vasc Biol. 1997;17:3174-84.
33. Itoh T, Nagaya N, Fujii T, Iwase T, Nakanishi N, Hamada K, et al. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med. 2004;169:34-8.